Affiliation:
1. Safety Assessment Dept., GlaxoSmithKline Research Centre, Verona, Italy
2. Drug Metabolism and Pharmacokinetics Dept., GlaxoSmithKline Research Centre, Verona, Italy
Abstract
Cardiovascular toxicity represents one of the major reasons for the termination of the development of drugs, even in late development phases. This growing issue is often not restricted to specific therapeutic areas, and it is gaining critical importance, in particular for chronically administered drugs, highlighting the limitations in terms of sensitivity of the current investigational paradigms. Furthermore, drug-related changes may become evident after long-term administration for different reasons, including accumulation of the drug in the heart. This article describes how the integrated use of investigational tools represents a powerful approach for the early identification and characterization of cardiotoxicity in preclinical development. Cardiac changes were observed in the dog after long-term oral administration of casopitant, a neurokinin 1 receptor antagonist, developed for the treatment of depression and anxiety. Different approaches and sensitive biomarkers were used in a time-course study to investigate the onset, progression, and reversibility of the lesion. The integrated evaluation of cardiovascular parameters, electron microscopy, troponin I, and natriuretic peptide results highlighted any minimal early changes, allowing the full and deep characterization of the lesion. The outcome of this study was the driver for drug development decision making on casopitant and backup drugs.
Subject
Cell Biology,Toxicology,Molecular Biology,Pathology and Forensic Medicine
Reference32 articles.
1. Drug-induced phospholipidosis
2. Cardiovascular Effects of Tricyclic and Tetracyclic Antidepressants
3. Cheville F. N. (1994). Ultrastructural Pathology: An Introduction to Interpretation. Iowa State University Press, Ames, IA.
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献